iSERA Lifesciences Ltd (ISERA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by iSERA Lifesciences Ltd on NSE and BSE, with an AI summary of each filing.
We hereby submit the revised un-Audited Financial result for Half year ended September 2026 under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Financial Result · 05 Nov 2026, 3:01 am
iSERA Lifesciences Reports Q2FY27 Standalone Net Loss of ₹13.11 Lakhs iSERA Lifesciences reported standalone net loss of ₹13.11 lakhs for the quarter ended 30th Sep'26, narrowing QoQ from a loss of ₹33.62 lakhs in Jun'26, compared to a profit of ₹0.70 lakhs in 30th Sep'25. Revenue from operations remained nil, while other income stood at ₹7.88 lakhs. Total expenses were ₹20.99 lakhs versus ₹33.62 lakhs in the prior quarter. For H1FY27, net loss widened to ₹46.73 lakhs from ₹0.84 lakhs YoY. Basic and diluted EPS for the quarter was negative ₹0.62.
We hereby submit that pursuant to Regulation 15(2) of SEBI (LODR) Regulations, 2015, the compliance with the corporate governance provisions as specified in Regulations 17, 18, 19, 20, ....
Others (Uncategorized) · 04 Nov 2026, 11:26 pm
iSERA Lifesciences Reports Exemption from SEBI LODR Corporate Governance Disclosures iSERA Lifesciences Limited has confirmed the non-applicability of Regulation 23(9) of SEBI (LODR) Regulations, 2015, regarding related-party transaction disclosures for the half-year ended 30th Sep'26. Under Regulation 15(2), the company qualifies for exemption from key corporate governance norms as its paid-up equity share capital remained below Rs. 10 Crore and net worth stood under Rs. 25 Crore as of 31st Mar'26. Consequently, mandatory compliance under Regulations 17 through 27 is not applicable.
We hereby submit the Un-Audited Financial Result for the quarter and half yearly ended September 2026
Financial Result · 04 Nov 2026, 11:13 pm
iSERA Lifesciences Reports Q2 FY27 Results with Continued Net Losses iSERA Lifesciences Limited reported nil revenue from operations for the quarter ended 30th Sep'26, matching Q1 FY27 and Q2 FY26. Total income stood at ₹7.88 lakh, derived entirely from other income. Total expenses reached ₹20.99 lakh compared to ₹33.62 lakh in Q1 FY27 and ₹0.30 lakh in Q2 FY26. The company posted a net loss of ₹13.11 lakh versus a loss of ₹33.62 lakh in Q1 FY27 and a profit of ₹0.70 lakh in Q2 FY26. Quarterly basic and diluted EPS was negative ₹0.62.
Outcome of the Board Meeting held today on 4th November 2026 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Outcome · 04 Nov 2026, 11:06 pm
iSERA Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs) ■ Revenue: 0.0 ■ EBITDA: -20.3 (-6656.7% YoY | +39.7% QoQ) ■ EBITDA Margin (%): 0.0 ■ PAT: -13.1 (Profit to Loss YoY | +61.0% QoQ) ■ EPS (INR): -0.62 (Profit to Loss YoY | +61.3% QoQ)
Isera Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the Un-Audited Financial ....
Intimation · 04 Nov 2026, 5:30 am
iSERA Lifesciences Board to Consider Q2 FY27 Results on 4th Nov'26 iSERA Lifesciences Limited announced that its Board of Directors is scheduled to meet on 4th Nov'26 to consider, approve, and take on record the standalone un-audited financial results for the quarter and half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in company equity shares has been closed for all designated persons from 1st Oct'26 and will reopen 48 hours after the declaration of the financial results.
Disclosure under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 - Continual Disclosure consequent to Preferential Allotment of ....
Others (Uncategorized) · 09 Oct 2026, 12:08 am
iSERA Lifesciences Allots Equity Shares via Preferential Share Swap iSERA Lifesciences Limited disclosed preferential share allotments on a share-swap basis executed on 1st Oct'26, intimating exchanges on 8th Oct'26 under SEBI PIT regulations. Key allottees include Shubhangi Dhanraj Garad, who acquired 27,55,000 equity shares (increasing holding to 14.46% post-allotment for Rs 13.28 crore), Sumeet Dhanraj Garad acquiring 11,92,000 shares (5.25% post-allotment for Rs 5.75 crore), Pratap Dadasaheb Deshmukh acquiring 7,85,500 shares (5.43% post-allotment), and Ritu Dhanraj Garad acquiring 7,46,000 shares (3.44% post-allotment), alongside multiple other promoter group members and individuals.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Archana Lonkar
Acquisition/ Disposal of Shares · 07 Oct 2026, 4:08 pm
Archana Lonkar Increases Stake in iSERA Lifesciences via Preferential Share Swap Promoter Archana Kakasaheb Lonkar acquired 4,95,000 equity shares (2.01% of expanded voting capital) of iSERA Lifesciences Ltd. via a preferential allotment (share swap) on 1st Oct'26. Consequently, her holding increased from 7,00,000 shares to 11,95,000 shares, representing 4.86% of the company's expanded equity base. The preferential issuance expanded iSERA's total equity share capital from Rs 8.41 cr (84,08,972 shares of Rs 10 each) to Rs 24.59 cr (2,45,91,772 shares of Rs 10 each).
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nandkumar Kadam
Acquisition/ Disposal of Shares · 07 Oct 2026, 4:02 pm
Nandkumar Subhash Kadam Acquires Additional Stake in iSERA Lifesciences via Preferential Allotment Promoter Nandkumar Subhash Kadam acquired 4,56,500 equity shares (1.86% voting capital) in iSERA Lifesciences on 1st Oct'26 via a preferential allotment (share swap). Following the transaction and the expansion of the company's total equity share capital base from 84,08,972 shares (₹8.41 Cr) to 2,45,91,772 shares (₹24.59 Cr), the acquirer’s total holding increased to 15,71,500 shares, representing a diluted stake of 6.39% compared to 13.26% prior to the capital expansion.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhairyasheel Yadav
Acquisition/ Disposal of Shares · 06 Oct 2026, 11:21 pm
iSERA Lifesciences Promoter Dhairyasheel Yadav Acquires Shares via Preferential Allotment Promoter Dhairyasheel Vasantrao Yadav acquired 4,50,500 equity shares (1.83% of post-issue equity capital) in iSERA Lifesciences Limited via a preferential allotment (share swap) on 1st Oct'26. Following this transaction, Yadav's total holding increased from 11,15,000 shares (13.26% of pre-issue capital) to 15,65,500 shares. Due to equity base expansion, the post-transaction holding represents 6.37% of the total diluted voting capital. The company's total equity base expanded significantly from 84,08,972 shares (Rs 8.41 cr) to 2,45,91,772 shares (Rs 24.59 cr).
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sumeet Dhanraj Garad
Acquisition/ Disposal of Shares · 06 Oct 2026, 10:43 pm
Sumeet Dhanraj Garad Increases Stake in iSERA Lifesciences to 5.25% Promoter Sumeet Dhanraj Garad acquired 11,92,000 equity shares (4.06% stake) of iSERA Lifesciences Limited on 1st Oct'26 via preferential allotment through a 1:1 share swap with iSERA Biological Limited. Following this transaction, his total holding increased from 1,00,000 shares (1.19%) to 12,92,000 shares, representing 5.25% of the total diluted voting capital. Consequently, iSERA Lifesciences' expanded equity share capital stands at Rs 24,59,17,720, comprising 2,45,91,772 equity shares of Rs 10 each fully paid-up.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pratap Dadasaheb Deshmukh & PACs
Acquisition/ Disposal of Shares · 06 Oct 2026, 9:57 pm
ISERA Lifesciences Promoter Group Dilutes Stake via Preferential Share Swap Allotment Promoter Pratap Dadasaheb Deshmukh and Persons Acting in Concert acquired 86,13,000 equity shares of ISERA Lifesciences Ltd via a preferential allotment (share swap) on 1st Oct'26. Consequently, their combined shareholding increased to 1,35,43,001 shares from 49,30,001 shares. However, due to the expansion of total equity capital from 84,08,972 shares (Rs 8.41 Cr) to 2,45,91,772 shares (Rs 24.59 Cr), the promoter group’s total voting rights decreased by 3.56% from 58.63% to 55.07% on an expanded, fully diluted base.
The Board of Directors of the Company, at its meeting held today i.e. October 01, 2026, has approved the allotment of 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) ....
Others (Uncategorized) · 01 Oct 2026, 5:34 pm
iSERA Lifesciences Allots 1.62 Crore Equity Shares via Share Swap The Board of Directors of iSERA Lifesciences Limited approved the preferential allotment of 1,61,82,800 fully paid-up equity shares (face value Rs. 10 each) at an issue price of Rs. 48.20 per share (including Rs. 38.20 premium) on 1st Oct'26. The issuance is for non-cash consideration via a 1:1 share swap to acquire shares of iSERA Biological Limited from 196 promoter and non-promoter allottees. Consequently, the company's paid-up equity share capital expands from 84,08,972 shares to 2,45,91,772 shares.
The Board of Directors of the Company, at its meeting held today i.e. October 01, 2026, has approved the allotment of 1,61,82,800 (One Crore Sixty-One Lakh Eighty-Two Thousand Eight Hundred) ....
Others (Uncategorized) · 01 Oct 2026, 5:31 pm
iSERA Lifesciences Approves Allotment of 1.62 Crore Shares via Share Swap On 1st Oct'26, iSERA Lifesciences Limited approved the preferential allotment of 1,61,82,800 equity shares of face value Rs. 10 each at an issue price of Rs. 48.20 per share (including Rs. 38.20 share premium). The issuance, executed on a 1:1 share swap basis for shares of iSERA Biological Limited, spans 196 promoter and non-promoter allottees. Consequently, the company's paid-up equity share capital expanded from 84,08,972 shares to 2,45,91,772 shares.
We are hereby submitting the Consolidated Scrutinizer's Report on E-voting during Annual General Meeting of iSEAR Lifesciences Limited (Formerly Known as Covidh Technologies Limited held ....
Annual General Meeting · 30 Sept 2026, 11:28 pm
We hereby submit the proceeding of the 34th AGM
Annual General Meeting · 29 Sept 2026, 10:05 pm
we hereby submit Annual Report of Annual General Meeting of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) for the financial year 2025-26
Others (Uncategorized) · 06 Sept 2026, 1:00 am
Notice of 34th Annual General Meeting ('AGM') of the Company is scheduled to be held on Tuesday, September 29, 2026 at 3:00 P.M. (IST) through video conference ('VC')/ other audio visual ....
Annual General Meeting · 06 Sept 2026, 12:44 am
We hereby informed that Board of Directors of the Company at its meeting held on Tuesday, the 01st September, 2026 discuss the agenda attached herewith.
Others (Uncategorized) · 01 Sept 2026, 9:34 pm
Isera Lifesciences Announces 34th Annual General Meeting for FY26 Isera Lifesciences (BSE: 534920) announced its Board of Directors has approved convening the 34th Annual General Meeting (AGM) on 29 Sep'26 at 3:00 PM via video conference. Key agenda items include the adoption of audited standalone financial statements for the year ending 31 Mar'26. The Board also approved the FY25-26 Annual Report. M/s. Anuj Gupta & Associates has been appointed as the scrutinizer for e-voting at the AGM. The meeting was held on 01 Sep'26.
We hereby submit the monitoring Agency Report for utilization of proceeds of Rights Issue of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) for the quarter ended ....
Others (Uncategorized) · 15 Aug 2026, 4:19 am
iSERA Lifesciences: Rights Issue Funds Utilization Update Q1 FY27 iSERA Lifesciences raised ₹8.08 crore via a rights issue in Nov '25. For the quarter ended Jun 30, 2026, the company utilized ₹1.82 crore: ₹0.93 crore for working capital, ₹0.40 crore for general corporate purposes, and ₹0.49 crore for issue expenses. The unutilized amount stands at ₹6.26 crore, with ₹6.00 crore invested in fixed deposits earning 5.25%-5.50% and a balance of ₹0.26 crore in a current account. The monitoring agency, Infomerics, reported no deviation from the stated objectives of the issue.
We are hereby submitting the Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
Financial Result · 07 Aug 2026, 8:19 pm
ISERA Lifesciences Reports Net Loss of ₹33.62 Lakhs for Q1 FY27 ISERA Lifesciences reported a standalone net loss of ₹33.62 lakhs for the quarter ended 30 Jun'26, compared to a net loss of ₹1.54 lakhs in the same quarter last year. The company recorded zero revenue from operations for the quarter, against nil in the prior year period. Total expenses stood at ₹33.62 lakhs. This contrasts sharply with the previous quarter ended 31 Mar'26, where the company posted a net profit of ₹54.98 lakhs. The negative EPS for Q1 FY27 was ₹(1.60).
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the Board of Directors of the Company at its meeting held on ....
Outcome · 07 Aug 2026, 8:09 pm
iSERA Lifesciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 0.0 (-100.0% QoQ) ■ EBITDA: -33.6 (-2083.1% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): 0.0 (-4898 bps QoQ) ■ PAT: -33.6 (-2083.1% YoY | Profit to Loss QoQ) ■ EPS (INR): -1.60 (Profit to Loss YoY | Profit to Loss QoQ)
Isera Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Intimation · 07 Aug 2026, 5:30 am
Isera Lifesciences Board Meeting to Approve Q1FY27 Results on 07 Aug'26 Isera Lifesciences (formerly Covidh Technologies) will hold a Board of Directors meeting on 07 Aug'26 to consider and approve its Un-Audited Financial Results for the quarter ended 30 Jun'26. The trading window for designated persons has been closed from 01 Jul'26 and will reopen 48 hours after the results are declared. This is in compliance with SEBI's Listing Obligations and Disclosure Requirements regulations.
We wish to inform you that iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) has issued a Corrigendum to the Notice of Postal Ballot dated April 21, 2026, vide Corrigendum ....
Others (Uncategorized) · 26 Jun 2026, 11:27 pm
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of iSERA Lifesciences ....
Others (Uncategorized) · 11 Jun 2026, 6:40 pm
iSERA Lifesciences (formerly Covidh) Finalizes Name and Ticker Change iSERA Lifesciences Limited, formerly Covidh Technologies Limited, announced its board meeting outcomes from Jun 11, '26. The company’s name change and new scrip ID "ISERA" (from "COVIDH") will be effective on the BSE from Jun 16, '26. The board also noted a BSE advisory regarding prior non-compliance with name change regulations and discussed corrective actions, including shareholder ratification. Additionally, a new corporate logo was adopted to reflect its strategic shift towards the life sciences sector, contingent on an ongoing preferential allotment/acquisition process.
We hereby submit the declaration w.r.t. non applicability of regulation 23(9) of SEBI LODR
Others (Uncategorized) · 22 May 2026, 1:45 am
Isera Lifesciences Claims Exemption from Corporate Governance Norms Isera Lifesciences (Scrip: 534920) has notified the BSE of the non-applicability of Regulation 23(9) of SEBI (LODR) Regulations for the half-year ended 31st Mar'26. Citing Regulation 15(2), the company claims exemption from specified corporate governance provisions. This is based on its Paid-up Equity Share Capital being under ₹10 Crore and Net Worth under ₹25 Crore as of 31st Mar'26. Consequently, the firm is not required to submit related party transaction disclosures for the period.